Latest Assistive Technology News

Control Bionics has secured a key regulatory milestone with its NeuroNode device now eligible for reimbursement under Germany’s statutory health insurance, paving the way for expanded European distribution.

Alcidion has secured regulatory approval for its AI-powered clinical tool in Australia and the UK, paving the way for commercial rollout in its largest markets. This milestone strengthens its position in healthcare technology and opens new sales avenues.

Oakridge International reports solid growth in healthcare technology revenues and product development progress, while navigating a potential legal claim from Teko International.

Control Bionics has secured a two-year US distribution agreement with AAC leader PRC-Saltillo to broaden access to its NeuroNode technology, enhancing communication options for users with complex needs.

Control Bionics has raised $3.8 million to fuel growth, forged a key distribution deal with Tobii, and integrated with Apple’s BCI protocol, while advancing its NeuroStrip and NeuroBounce platforms.

Talius Group reported a positive operating cash flow for the December quarter, alongside a 3% rise in subscriptions and a $4 million capital placement. The company also announced a CEO succession and expanded its international footprint with new pilot programs.

Control Bionics has partnered with Tobii Dynavox to pilot its NeuroNode technology across five US states, aiming to enhance communication access for users of augmentative devices.

Metal Hawk Limited’s recent Sub-Audio Magnetics survey at Leinster South has pinpointed a promising new gold target north of the Tysons prospect, setting the stage for a targeted drilling campaign in February 2026.

Control Bionics has secured $3.25 million through a discounted share placement, aiming to boost its assistive and neurotechnology product growth globally.

Control Bionics has integrated Apple’s Brain-Computer Interface protocol into its NeuroNode products, promising simpler setup and enhanced communication for users with severe impairments.

Oakridge International reports robust Q1 2025 results with strong sales and technology advances, while managing a potential legal claim.

Control Bionics reports a strong start to FY26 with nearly 10% revenue growth, expanded US reimbursement coverage, and advancing commercialization of its NeuroNode and NeuroStrip technologies.